565 Likes UCB takes the lead for her at EULAR and WCD Posted by Andrea Christopher, Global Communications & Company Reputation 14-Jun-2019 UCB honored at EULAR 2019 meetingUCB proudly received the FOREUM (Foundation for Research in Rheumatology) Platinum Recognition Award during the opening plenary session at this year’s Annual European Congress of Rheumatology (EULAR 2019) in Madrid (June 12 - 15). FOREUM promotes health in people living with rheumatic and musculoskeletal diseases through effective research. Our ongoing partnership with FOREUM is critical for improving patient outcomes and furthering a more sustainable healthcare system. Solving today’s complex healthcare challenges requires a multi-stakeholder approach to ensure effective and innovative medicines and technologies are available, accessible and affordable to all patients living with chronic rheumatic and musculoskeletal diseases. Our partnership will further our ambition to bring novel solutions vital to improving existing care and quality of life for these patients. UCB also showcased the depth of our immunology research with multiple presentations on the treatment of axial spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis. We also presented patient research demonstrating the need to educate and engage women with chronic inflammatory diseases about their disease state and family planning. Great presence at World Congress of DermatologyUCB hosted a commercial booth and several key symposium sessions at The World Congress of Dermatology (WCD), in Milan (June 10-15). WCD is held every four years and attracts over 20,000 attendees interested in advancements in dermatology. As part of our ongoing commitment to addressing unique considerations for women with psoriasis, UCB sponsored a symposium on the unmet needs of women of childbearing age with psoriatic disease, as well as meet-the-expert sessions on improving care for this important patient population. UCB also hosted a symposium on patient satisfaction in psoriatic disease and an evolved understanding of IL-17A and IL-17F, an important topic for improving psoriasis treatment. Our achievements at both meetings are a strong signal to the community of our commitment to serving as partners in care, supporting patients, rheumatologists, and dermatologists dealing with challenging treatment situations and improving the clinical understanding of their needs. Our aim is to bring real world value to patients with significant unmet needs. Leave a Comment You must have JavaScript enabled to use this form. Please enter your name Please enter your email address By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here. CAPTCHA Get new captcha! What code is in the image? Enter the characters shown in the image. Leave this field blank
